Szliszka and coworkers observed that combination-therapy of bladder cancer cells with TRAIL and chrysin led to higher sensitization of bladder cancer cells to TRAIL prompted cytotoxicity [147, 148]. The gene discussed is TNFSF10; the disease is urinary bladder carcinoma.